Balances - Correction of the Requirements in the U.S. Pharmacopoeia (USP)
Recommendation
20/21 October 2026
Performance Evaluation and Monitoring for compliant Analytical Procedures and Processes
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In the Pharmacopoeial Forum 40(1) a short-term revision of the General Chapter <41> with regard to balances was announced as "interim revision announcement".
Questions that arrived at the USP indicate that there is a potential problem with the requirement of repeatability in the verification of scales. If you follow the procedure as described, the use of a large test weight can cause false positive results.
To resolve this problem, the expert group of the USP proposes a modified test in which the "smallest desired net weight" is now incorporated in the formula for the repeatability as well.
If there are no contrary comments, this "interim revision announcement" will become effective as of 1 July 2014.
All other information are available on the USP website of the Pharmacopeial Forum (PF).
Source: USP - http://www.USP.org
Related GMP News
07.10.2026Analytical Quality Group Developments May through August 2026
07.10.2026Two New FDA Warning Letters Put OOS Investigations in Focus
07.10.2026Pharmeuropa: Revision Proposed for Chapter 2.5.32 on Coulometric Karl Fischer Water Determination
30.09.2026The Relationship between the BP and the Ph. Eur.
30.09.2026New Japanese Pharmacopoeia Drafts (September 2026) Open for Public Comment
30.09.2026EMA publishes final ICH M13B Guideline and Q&A on Bioequivalence